Closing the LDL-C Gap: Optimizing Lipid-Lowering Therapy in ASCVD

Clinicians shift from “hyper” labels to atherosclerosis risk, using diabetes markers and LDL targets to prevent heart attack and stroke.

Learn how clinicians personalize LDL-lowering therapy, address statin fears, and choose pills or injections to hit cholesterol goals despite cost barriers.

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

Why patients quit cholesterol therapy—and how LDL checkups, reminders, and longer-acting injectables improve lifelong medication adherence.

Learn how clinicians reach ultra-low LDL targets in high-risk patients using ezetimibe, PCSK9s, and smarter insurance documentation.

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.